Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.

The development adds further growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV.
Gemcovac became the first saRNA vaccine to obtain approval for use in humans in India.
The filing is based on data from six clinical trials in subjects of the age 18 years and above.
Four programmes of F-star are currently in the clinic while various other undisclosed programmes are in the developmental stage.
The vaccine doses for Taiwan would be the first shipment to a nation participating in the COVAX Facility.
In a Phase III trial, treatment with Voxzogo offered transient declines in blood pressure.
The latest provisional registration is based on findings from two Phase II trials and the COV-BOOST trial of the vaccine.
The approval is based on clinical data from the Phase III RATIONALE 309 clinical trial of tislelizumab plus chemotherapy.
Thank you for subscribing to Pharmaceutical Technology